+86-21-58356573
LANGUAGE

Company news

ImmuneOnco Biopharma received Pudong New District Finance Bureau 100 thousand grants

2017/11/1 0:00:00Click:164

  On October 31, 2017, ImmuneOnco Biopharma received Pudong New District Finance Bureau 100 thousand yuan grants. The project is the technology contract transaction project in Pudong New district, the top level of 100 thousand.

     On June 8 of 2016, ImmuneOnco Biopharma Co., Ltd., an emerging biotech company fully focusing on discovery and development of tumor immunotherapy, today announced two collaboration agreements signed respectively with Wo-Yun Investment LLP and Genor Biopharma Co., Ltd, the latter of which is a wholly-owned subsidiary of a public listed biopharmaceutical company, Walvax Biotechnology Co., Ltd. Under the terms of agreements, Wo-Yun Investment Company will have the right to further develop and commercialize two of ImmuneOnco’s proprietary TANK (Target-Activated NK)TM cell therapeutic products, PD1-TANK and CD19-TANK in China. In return, ImmuneOnco is eligible to receive upfront as well as milestone payments plus sales royalties in the future. ImmuneOnco Biopharma and Genor Biopharma cooperation, each play their own advantages, continue to develop new immunotherapy drug for Chinese cancer patients with independent intellectual property rights.